Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?

ABSTRACT:

SUBMITTER: Lemmon C 

PROVIDER: S-EPMC7578493 | biostudies-literature | 2020 Sep

REPOSITORIES: biostudies-literature